Cabazitaxel

Generic Name: Cabazitaxel

Brand Names: Jevtana, Cabazitaxel Accord

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₇NO_₁₄

CAS Number: 183133-96-2

Unique Ingredient Identifier: 51F690397J

Background: Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...

Indication: 用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Associated Therapies: -

Clinical Trials

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

Phase 2

Terminated

Conditions: Lung Cancer
Progressive Brain Metastases
Breast Cancer
Recurrent Brain Metastases

Interventions: Drug: Cabazitaxel

First Posted Date: 2014-06-18

Last Posted Date: 2018-01-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 8

Registration Number: NCT02166658

Locations: 🇩🇪
Kliniken Nordoberpfalz, AG Klinikum Weiden, Medizinische Kliniken I, Weiden, Bayern, Germany

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Phase 2

Conditions: Non-seminomatous Germ-cell Tumors

Interventions: Drug: Cabazitaxel

First Posted Date: 2014-04-15

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 34

Registration Number: NCT02115165

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

Phase 3

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Taxotere
Drug: Jevtana

First Posted Date: 2014-01-24

Last Posted Date: 2017-08-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 195

Registration Number: NCT02044354

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Phase 2

Withdrawn

Conditions: Advanced Prostate Cancer

Interventions: Drug: BKM 120
Drug: Cabazitaxel

First Posted Date: 2014-01-14

Last Posted Date: 2016-02-11

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02035124

Locations: 🇺🇸
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation

Phase 1

Withdrawn

Conditions: Prostatic Neoplasms

Interventions: Drug: cabazitaxel

First Posted Date: 2013-11-11

Last Posted Date: 2014-03-19

Lead Sponsor: Nova Scotia Cancer Centre

Registration Number: NCT01981668

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2013-10-08

Last Posted Date: 2018-04-18

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 65

Registration Number: NCT01956149

Locations: 🇩🇪
Krankenhaus Dresden Friedrichstadt, Dresden, Germany
🇩🇪
Krankenhaus Nordwest, Frankfurt am Main, Germany
🇩🇪
Universitätsklinikum Jena, Jena, Germany

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

Phase 3

Active, not recruiting

Conditions: Adenocarcinoma of Prostate
Progression of Prostate Cancer

Interventions: Radiation: Pelvic radiotherapy
Drug: Cabazitaxel
Radiation: prostate radiotherapy

First Posted Date: 2013-09-27

Last Posted Date: 2024-04-09

Lead Sponsor: UNICANCER

Target Recruit Count: 761

Registration Number: NCT01952223

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Phase 2

Terminated

Conditions: Metastatic Breast Cancer With Intracranial Metastases

Interventions: Drug: cabazitaxel
Drug: lapatinib

First Posted Date: 2013-09-04

Last Posted Date: 2017-07-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 11

Registration Number: NCT01934894

Locations: 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care Inc., Cincinnati, Ohio, United States
🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States

and more 1 locations

Ph II Cabazitaxel DD Liposarcoma

Phase 2

Completed

Conditions: Dedifferentiated Liposarcoma

Interventions: Drug: Cabazitaxel

First Posted Date: 2013-08-01

Last Posted Date: 2021-09-14

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 42

Registration Number: NCT01913652

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen (117), Antwerpen, Belgium
🇮🇹
Istituto Oncologico Veneto IRCCS - Ospedale Busonera (3908), Padova, Italy
🇫🇷
Centre Leon Berard (227), Lyon, France

and more 8 locations

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

Phase 2

Withdrawn

Conditions: Non Small Cell Lung Cancer
Brain Metastasis
Breast Cancer

Interventions: Drug: Cabazitaxel
Procedure: Contrast-enhanced whole brain MRI

First Posted Date: 2013-07-31

Last Posted Date: 2014-07-24

Lead Sponsor: Jules Bordet Institute

Registration Number: NCT01913067

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy